Literature DB >> 6434221

Diazepam tapering in detoxification for high-dose benzodiazepine abuse.

M Harrison, U Busto, C A Naranjo, H L Kaplan, E M Sellers.   

Abstract

The clinical characteristics and management of patients who abuse high doses of benzodiazepines are not well described. In a prospective open study, 23 subjects who abused high doses of benzodiazepines were admitted for detoxification. Urine or blood test results confirmed benzodiazepine use in all but one subject and multiple drug use in eight (35%). Median benzodiazepine dose was 150 mg (range 40 to 500 mg) of diazepam equivalent. Initial plasma concentrations (diazepam: median = 1245 ng/ml; desmethyldiazepam: median = 2961 ng/ml) were 400% to 800% higher than usual therapeutic concentrations. For detoxification, subjects were given a loading dose of diazepam equal to approximately 40% their reported daily consumption. This was followed with daily tapering of diazepam by 10%. This regimen resulted in a slow and gradual decline in drug concentrations. Withdrawal symptoms were assessed daily. Sixteen subjects completed detoxification in the hospital without complications. One subject became paranoid and confused on day 7 of withdrawal. This was attributed to a too-low initial loading dose and too-rapid tapering, which resulted in rapid drug elimination. Gradual reduction of diazepam dose appears to be an effective and safe approach for detoxifying abusers of high doses of benzodiazepines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6434221     DOI: 10.1038/clpt.1984.214

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

Review 2.  Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective.

Authors:  U Busto; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

3.  Benzodiazepines: dependence and a therapeutic approach to gradual withdrawal.

Authors:  D Blais; L Petit
Journal:  Can Fam Physician       Date:  1990-10       Impact factor: 3.275

Review 4.  Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring.

Authors:  Anna Basińska-Szafrańska
Journal:  Eur J Clin Pharmacol       Date:  2021-01-03       Impact factor: 2.953

5.  Benzodiazépines: dépendance et approche thérapeutique pour un retrait graduel.

Authors:  D Blais; B Pharm; L P Pharm
Journal:  Can Fam Physician       Date:  1987-11       Impact factor: 3.275

Review 6.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

7.  Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management.

Authors:  E M Sellers
Journal:  CMAJ       Date:  1988-07-15       Impact factor: 8.262

8.  Use of a long-acting substitute in detoxification from benzodiazepines: safety (accumulation) problems and proposed mitigation procedure.

Authors:  Anna Basińska-Szafrańska
Journal:  Eur J Clin Pharmacol       Date:  2022-09-17       Impact factor: 3.064

9.  High-Dose Benzodiazepine Dependence: A Qualitative Study of Patients' Perceptions on Initiation, Reasons for Use, and Obtainment.

Authors:  Michael Liebrenz; Marcel Schneider; Anna Buadze; Marie-Therese Gehring; Anish Dube; Carlo Caflisch
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

Review 10.  Benzodiazepine high-doses: The need for an accurate definition.

Authors:  Jean-Marc Cloos; Christopher Y S Lim Cow; Valéry Bocquet
Journal:  Int J Methods Psychiatr Res       Date:  2021-07-31       Impact factor: 4.035

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.